Dacomitinib Delayed Progression for NSCLC, Increased Adverse Events

Dacomitinib delayed progression of EGFR-positive non –small-cell lung cancer, but led to more adverse events compared with gefitinib. (Source: CancerNetwork)

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2r2edOy
via IFTTT